TRIAL DETAIL
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 08/01/2011 |
Age of Trial (yrs) 13.7 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor + MEK inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CMEK162X2101, EudraCT 2011-001083-22 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Novartis Pharmaceuticals 800-340-6843 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Singapore |
Singapore |
||||
55 Fruit Street |
Boston |
MA |
02114 |
USA |
|
Detroit |
MI |
48201 |
USA |
||
1275 York Ave |
New York |
NY |
10065 |
USA |
|
Greenville |
SC |
29615 |
USA |
||
Hufelandstr. 55 |
Essen |
45122 |
Germany |
||
Heidelberglaan 100 |
Utrecht |
3584 CX |
Netherlands |
||
119-129 |
Barcelona |
08035 |
Spain |